JPWO2020053541A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020053541A5 JPWO2020053541A5 JP2021538933A JP2021538933A JPWO2020053541A5 JP WO2020053541 A5 JPWO2020053541 A5 JP WO2020053541A5 JP 2021538933 A JP2021538933 A JP 2021538933A JP 2021538933 A JP2021538933 A JP 2021538933A JP WO2020053541 A5 JPWO2020053541 A5 JP WO2020053541A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- vesicle
- cholesterol
- formulation
- pharmaceutical agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 20
- 239000008177 pharmaceutical agent Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 7
- 102000004338 Transferrin Human genes 0.000 claims description 7
- 108090000901 Transferrin Proteins 0.000 claims description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002442 glucosamine Drugs 0.000 claims description 7
- 239000012581 transferrin Substances 0.000 claims description 7
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- HSVDYEDYDOKETI-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)octadecan-3-one Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)(CO)CO HSVDYEDYDOKETI-UHFFFAOYSA-N 0.000 claims description 5
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940093541 dicetylphosphate Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 229940124307 fluoroquinolone Drugs 0.000 claims description 3
- 229960003376 levofloxacin Drugs 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 229940040944 tetracyclines Drugs 0.000 claims description 3
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 230000002051 biphasic effect Effects 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 241001136175 Burkholderia pseudomallei Species 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940118764 francisella tularensis Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- -1 or a variant Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000007723 transport mechanism Effects 0.000 description 2
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1814959.1A GB201814959D0 (en) | 2018-09-14 | 2018-09-14 | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
| GB1814959.1 | 2018-09-14 | ||
| PCT/GB2019/000134 WO2020053541A1 (en) | 2018-09-14 | 2019-09-13 | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501423A JP2022501423A (ja) | 2022-01-06 |
| JP2022501423A5 JP2022501423A5 (https=) | 2022-09-21 |
| JPWO2020053541A5 true JPWO2020053541A5 (https=) | 2022-09-21 |
| JP7487892B2 JP7487892B2 (ja) | 2024-05-21 |
Family
ID=64013381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538933A Active JP7487892B2 (ja) | 2018-09-14 | 2019-09-13 | 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11524080B2 (https=) |
| EP (1) | EP3849511B1 (https=) |
| JP (1) | JP7487892B2 (https=) |
| AU (1) | AU2019337456B9 (https=) |
| CA (1) | CA3113047A1 (https=) |
| DK (1) | DK3849511T3 (https=) |
| GB (2) | GB201814959D0 (https=) |
| WO (1) | WO2020053541A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4125845A4 (en) * | 2020-04-02 | 2024-05-15 | Southern Research Institute | NEW 2-PYRIMIDONE ANALOGUES AS EFFECTIVE ANTIVIRAL AGENTS AGAINST ALPHAVIRES |
| CN116350588B (zh) * | 2023-01-13 | 2024-09-24 | 华中科技大学 | 一种载抗生素微生物囊泡及其制备方法和应用 |
| GB202303291D0 (en) * | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323561A (en) * | 1977-09-06 | 1982-04-06 | Temple University Of The Commonwealth System Of Higher Education | Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants |
| JPH04159216A (ja) * | 1990-10-22 | 1992-06-02 | Japan Tobacco Inc | グルコサミン誘導体を膜材として含有するリポソーム |
| GB9515868D0 (en) | 1995-08-02 | 1995-10-04 | Proteus Molecular Design | Therapeutic method |
| US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
| CA2721870C (en) * | 2008-04-21 | 2020-12-22 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
| AU2010270722B2 (en) * | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US9907746B2 (en) * | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| GB0916630D0 (en) | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
| MX342138B (es) * | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| WO2013059617A1 (en) * | 2011-10-21 | 2013-04-25 | Ndsu Research Foundation | Liposome compositions and methods of use |
| US20140328876A1 (en) * | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
| US20140356399A1 (en) * | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) * | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| US9969794B2 (en) * | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9539273B2 (en) * | 2012-08-04 | 2017-01-10 | Edh Biotech Corp | Targeted delivery of anti-fungal agents |
| US9987227B2 (en) * | 2013-10-22 | 2018-06-05 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
| US9968555B2 (en) | 2014-04-08 | 2018-05-15 | Aradigm Corporation | Liposomal formulations that form drug nanocrystals after freeze-thaw |
| MX386433B (es) * | 2014-08-14 | 2025-03-18 | L E A F Holdings Group Llc | Fármaco de afinidad encapsulado en liposoma. |
-
2018
- 2018-09-14 GB GBGB1814959.1A patent/GB201814959D0/en not_active Ceased
-
2019
- 2019-09-12 GB GB1913128.3A patent/GB2578678B/en active Active
- 2019-09-13 DK DK19778580.1T patent/DK3849511T3/da active
- 2019-09-13 WO PCT/GB2019/000134 patent/WO2020053541A1/en not_active Ceased
- 2019-09-13 CA CA3113047A patent/CA3113047A1/en active Pending
- 2019-09-13 US US17/273,059 patent/US11524080B2/en active Active
- 2019-09-13 JP JP2021538933A patent/JP7487892B2/ja active Active
- 2019-09-13 EP EP19778580.1A patent/EP3849511B1/en active Active
- 2019-09-13 AU AU2019337456A patent/AU2019337456B9/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170165375A1 (en) | Antibiotic protocells and related pharmaceutical formulations and methods of treatment | |
| US20250255978A1 (en) | Drug-delivery nanoparticles and treatments for drug-resistant cancer | |
| KR20120104173A (ko) | 치료제의 미셀 캡슐화 | |
| AU767892B2 (en) | New combined preparation for the treatment of neoplasic diseases or of infectious diseases | |
| JP2022501423A5 (https=) | ||
| HK1054201B (zh) | 高不溶性铂配合物的脂质复合物和脂质体 | |
| JP2022507615A (ja) | 治療用デンドリマー | |
| TWI593415B (zh) | 艾拉阿糖胞苷衍生物之非經腸調配物 | |
| PL183040B1 (pl) | Kompozycja farmaceutyczna nierozpuszczalnych w wodzie kamptotecyn | |
| TW202216122A (zh) | 微脂體製劑 | |
| WO2023136689A1 (ko) | 생분해성 에스터 결합을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
| JP2008534525A (ja) | リン脂質のポリエチレングリコール誘導体に包み込まれたアンスラサイクリン系抗腫瘍抗生物質のナノミセル製剤 | |
| JPH0278699A (ja) | ベンゾイルウレア系化合物・アルブミン複合体 | |
| AU779922B2 (en) | Formulations for parenteral use of estramustine phosphate and amino acids | |
| JPWO2020053541A5 (https=) | ||
| JP7487892B2 (ja) | 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用 | |
| BE1024228B1 (fr) | Nouvelles formulations d'adjuvants | |
| JPWO1999048531A1 (ja) | 肝炎治療剤 | |
| CN101370783B (zh) | 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法 | |
| JPH0136445B2 (https=) | ||
| CZ296169B6 (cs) | Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo | |
| CN110787301A (zh) | CTLA-4 Aptamer靶向共负载PD-1 siRNA纳米颗粒及其制备和应用 | |
| CN1374857A (zh) | 肠胃外用磷雌氮芥和磺烷基醚环化糊精制剂 | |
| CN1511037A (zh) | 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂 | |
| JP2004504346A (ja) | 骨転移の治療におけるリン酸エストラムスチンの使用 |